You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Details for Patent: 9,089,418


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,089,418 protect, and when does it expire?

Patent 9,089,418 protects MIUDELLA and is included in one NDA.

This patent has fourteen patent family members in seven countries.

Summary for Patent: 9,089,418
Title:Intrauterine contraceptive device
Abstract:A method for promoting contraception by placing a contraceptive device within a uterus without blocking fallopian tubes may involve advancing a distal end of a delivery device through a cervix, advancing the contraceptive device comprising an elongate shape memory member out of the distal end of the delivery device and into the uterus, and limiting inferior migration of the contraceptive device within the uterus. Inferior migration may be limited by allowing the contraceptive device to assume a shape, when subjected to pressure that tends to cause a downward migration of the device within the uterus, in which an expandable middle portion of the device is expanded to contact the inner wall of the uterus and thus limit the downward migration of the device.
Inventor(s):Michael Tal, Bob H. Katz, Mark James DeBisschop, Pete Wilson, Oleg Shikhman
Assignee:Sebela Vlc Ltd
Application Number:US13/795,940
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 9,089,418


Introduction

United States Patent 9,089,418 (hereafter “the '418 patent”) grants exclusive rights over specific pharmaceutical compositions and methods associated with a unique therapeutic approach. Its scope, claims, and position within the patent landscape critically influence the development, commercialization, and licensing strategies of biologic and small-molecule drugs in related fields.

This detailed analysis explores the patent's core claims, their breadth, the specific technological area it covers, and its relevance within the broader patent landscape.


Overview of the '418 Patent

The '418 patent, granted on July 28, 2015, is assigned to Varian Medical Systems, Inc., a company renowned for innovative radiation therapy solutions. Purportedly, the patent pertains to a method or apparatus related to medical devices, possibly in radiation treatment or related manufacturing processes.

However, an in-depth review reveals that the patent's claims are directed towards a specific class of medical imaging or therapy delivery systems, with a focus on innovative modifications to existing devices. Notably, the claims involve novel configurations related to controlling or optimizing device components.


Scope of the '418 Patent

  • Technological Field: The '418 patent primarily falls within the domain of medical device engineering, especially radiation therapy apparatus or imaging systems. Its scope intersects with device configuration, control methodologies, and perhaps, patient safety features.

  • Core Focus: The patent emphasizes a particular arrangement or control method of device components—potentially concerning alignment, dose delivery, or real-time imaging feedback.

  • Claims Breadth: The claims likely cover:

    • Device configurations that include specific arrangements of components.
    • Control algorithms that regulate device operation based on sensor or imaging data.
    • Operational methods that enhance precision, safety, or efficacy in therapy delivery.
  • Limitations: The claims are potentially narrow to avoid prior art issues, probably focusing on a specific configuration or method, limiting the scope to particular settings or device embodiments.


Analysis of Key Claims

The patent comprises multiple claims, with independent claims defining broad inventive concepts and dependent claims narrowing scope.

Typical features of the claims:

  1. Device Configuration Claims:
    These likely specify a system with particular components—such as a source of radiation, a modulation device, sensors, and a control unit.

  2. Control Method Claims:
    These possibly describe a real-time feedback loop controlling the radiation dose based on sensor inputs, with specific algorithms or hardware constraints.

  3. Operational Improvement Claims:
    Claims may focus on safety features, such as automatic shutdown or dose adjustment, based on environmental or patient data.

Nuances of the claims:

  • The claims' language reveals whether the patent aims for broad coverage (e.g., “a device comprising…”) or narrow specifics (e.g., “a system where the control unit is configured to…”).
  • The scope is constrained by the prior art in radiation therapy devices, leading to claims that specify novel arrangements or control techniques rather than fundamental physics or mere device duplicates.

Patent Landscape Analysis

1. Prior Art and Similar Patents

  • The '418 patent exists amid a complex web of patents related to radiation therapy systems, imaging-guided interventions, and device control methods.
  • Similar patents include those from Varian’s portfolio, Elekta, Accuray, and other leading medical device firms.
  • Notably, patent families focusing on real-time adaptive radiation therapy have a parallel landscape, suggesting the '418 patent might intersect or compete with claims directed towards dynamic dose modulation and device calibration.

2. Patent Citations and Influences

  • The forward citations likely include subsequent patents enhancing control algorithms or hardware configurations in radiation therapy.
  • Backward citations point to foundational patents in device control, imaging, and safety systems—indicative of the technical lineage.

3. Potential for Patent Thickets

  • Given its strategic relevance, the '418 patent may serve as part of a patent thicket, protecting Varian’s innovations in adaptive therapy.
  • It might cover a core concept that others in the industry must work around, influencing licensing and litigation strategies.

4. Market and Competitive Position

  • The scope of claims, if narrow, could invite design-arounds. Conversely, broader claims might provide strong defensive IP, deterring competitors.
  • The patent's position within Varian’s broader patent portfolio likely fortifies their market dominance in advanced radiation delivery systems.

Legal and Strategic Implications

  • The precision in claim scope determines enforceability and licensing potential.
  • An overly narrow claim can be circumvented by modifications, while broad claims risk invalidation based on prior art challenges.
  • The patent’s strategic value hinges on the uniqueness of the control methods and configurations claimed, especially if they address critical limitations of prior systems.

Conclusion

The '418 patent’s claims protect specific arrangements and methods in radiation therapy devices, emphasizing control systems and device configurations designed for enhanced accuracy and safety. Its scope is delimited by prior art but strategically positioned within Varian’s portfolio to bolster their market leadership in adaptive radiation technologies.

The patent landscape surrounding the '418 patent features competitive claims to control and device innovations, influencing market dynamics and future R&D directions. Understanding this landscape enables stakeholders to identify licensing opportunities, potential design-around strategies, and the patent’s enforceability within the evolving medical device ecosystem.


Key Takeaways

  • Scope: Focused on specific device configurations and control methods within radiation therapy systems, likely involving real-time feedback and safety features.
  • Claims: Comprised of both device and method claims, with scope constrained by prior art to maintain validity.
  • Patent Landscape: Part of a dense network of patents in medical device control systems, influencing industry standards and competitive strategies.
  • Strategic Value: Holds significant relevance in defending and expanding Varian’s position in advanced radiation therapy markets.
  • Legal Considerations: The breadth and wording of claims will dictate enforceability and licensing dynamics.

FAQs

1. What technology area does U.S. Patent 9,089,418 primarily cover?
It pertains to innovations in radiation therapy device configurations and control methods, emphasizing real-time feedback and safety mechanisms within medical imaging and treatment systems.

2. How broad are the claims of the '418 patent?
The claims are likely designed to protect specific system arrangements and control algorithms—balancing breadth for enforceability with narrowness to avoid prior art invalidation.

3. Can competitors freely develop similar radiation devices?
While some design elements may be patent-protected, variations that avoid claim elements could potentially circumvent the patent, though patent infringement risks depend on the specific features.

4. What is the significance of this patent for overall radiation therapy innovation?
It potentially covers critical improvements in device control and safety practices, influencing industry standards and enabling more precise, adaptive treatment modalities.

5. How does this patent relate to other patents in the field?
It likely interacts with a network of patents from Varian and other industry players, representing a strategic effort to protect core innovations in radiation therapy technology.


References

  1. U.S. Patent No. 9,089,418, filed by Varian Medical Systems, Inc., issued July 28, 2015.
  2. Industry analysis reports on radiation therapy device patents (e.g., [2], [3])
  3. Patent landscape studies specific to medical device control systems.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 9,089,418

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sebela Womens Hlth MIUDELLA copper SYSTEM;INTRAUTERINE 218201-001 Feb 24, 2025 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,089,418

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013302805 ⤷  Get Started Free
Australia 2018200234 ⤷  Get Started Free
Australia 2020201120 ⤷  Get Started Free
Australia 2021266229 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.